Last reviewed · How we verify
NCT04433871: PEDONCOVID
COVID-19 in Pediatric Oncology and Hematology Centers in France
trial testing No intervention, observational in Covid-19 in 300 participants. Status unknown.
27 April 2022
Quick facts
| Lead sponsor | University Hospital, Caen |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 27 April 2020 |
| Primary completion | 27 April 2022 |
| Estimated completion | 27 April 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- No intervention, observational
Conditions studied
Sponsor
University Hospital, Caen
Who can join
Adults 1 Month to 30, any sex, with Covid-19 or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Since the description of the first cases of infection in December 2019 in the Hubei province in China, a new coronavirus, called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), emerged and caused a pandemic. This new virus is responsible for an infectious disease with respiratory and potent severe symptoms, called COVID-19 (coronavirus disease 2019). The first data concerned essentially the adult population and gave a clinical description of the disease. However, data is missing in the pediatric population. The first published studies indicate that children seem to have a lower risk to get a severe form of COVID-19. Except the case of a child with leukemia recently described with the diagnosis of COVID-19, there is currently no data about pediatric patients with an oncology history or under chemotherapeutic drugs. Cancers are rare among children and is estimated to concern about 1700 new cases in a year in France. Malignant tumor or its treatment can affect self-immunity, which could favor SARS-CoV-2 infection or its aggravation. Thus, the investigators propose in this study to collect data about French children with a cancer and diagnosed with COVID-19.The analysis of the collected data will refine clinical characteristics of SARS-CoV-2 infection in this population. It will be critical for elaborating recommendations for the management of COVID-19 in children with cancer.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237 -
Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology.
Rouger-Gaudichon J, Thébault E, Félix A, Phulpin A, et al · · 2020 · cited 25× · PMID 33212828 · DOI 10.3390/cancers12113398 -
COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE).
Rouger-Gaudichon J, Bertrand Y, Boissel N, Brethon B, et al · · 2021 · cited 11× · PMID 33781551 · DOI 10.1016/j.bulcan.2021.02.004
Verify or expand the search:
- PubMed search for NCT04433871
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention, observational
Trials testing the same drug.
- NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
- NCT06396520 — Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy · recruiting
- NCT05169164 — Latin American Surgical Outcomes Study · completed
- NCT03326154 — Post-Cholecystectomy Quality of Life · recruiting
- NCT03866291 — ESBL in Patients Returning to Sweden With Traveller's Diarrhoea · completed
Other recruiting trials for Covid-19
Currently open trials in the same condition.
- NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
- NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
- NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
- NCT04568148 — COVID-19 Biorepository · active not recruiting
- NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting
Other University Hospital, Caen trials
Trials by the same sponsor.
- NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
- NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
- NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
- NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
- NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04433871 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
- Last refreshed: 16 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04433871.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing